BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23044922)

  • 21. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells.
    Kong L; Zhao Q; Wang X; Zhu J; Hao D; Yang C
    BMC Complement Altern Med; 2014 Dec; 14():481. PubMed ID: 25496242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
    Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
    PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
    Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
    Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1.
    Lee JM; Park H; Noh AL; Kang JH; Chen L; Zheng T; Lee J; Ji SY; Jang CY; Shin CS; Ha H; Lee ZH; Park HY; Lee DS; Yim M
    J Immunol; 2012 Dec; 189(11):5284-92. PubMed ID: 23109727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
    Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
    J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation.
    Fuji H; Ohmae S; Noma N; Takeiri M; Yasutomi H; Izumi K; Ito M; Toyomoto M; Iwaki S; Takemoto K; Seo S; Taura K; Hida S; Aoyama M; Ishihama Y; Hagiwara M; Takeda N; Hatano E; Iwaisako K; Uemoto S; Asagiri M
    Biochem Biophys Res Commun; 2018 Sep; 503(2):544-549. PubMed ID: 29800570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways.
    Nie S; Xu J; Zhang C; Xu C; Liu M; Yu D
    Biochem Biophys Res Commun; 2016 Jan; 470(1):61-67. PubMed ID: 26740180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells.
    Blüml S; Friedrich M; Lohmeyer T; Sahin E; Saferding V; Brunner J; Puchner A; Mandl P; Niederreiter B; Smolen JS; Schabbauer G; Redlich K
    Ann Rheum Dis; 2015 Jan; 74(1):227-33. PubMed ID: 24078675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
    Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
    J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production.
    Nakamura T; Kukita T; Shobuike T; Nagata K; Wu Z; Ogawa K; Hotokebuchi T; Kohashi O; Kukita A
    J Immunol; 2005 Nov; 175(9):5809-16. PubMed ID: 16237073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.